7 results about "Mouse Kidney" patented technology

The application discloses application of a rehmannia glutinosa extract in preparation of drugs for treating kidney injury caused by cisplatin. The application of the rehmannia glutinosa extract in preparation of drugs for preventing and / or treating kidney injury caused by cisplatin; a preparation method of the rehmannia glutinosa extract, comprising the following steps: S1, adding water to the rehmannia glutinosa to perform extraction, to obtain a rehmannia glutinosa water extract; S2, adding ethyl acetate to the rehmannia glutinosa water extract to perform extraction, separating ethyl acetate phase and water phase, to obtain the rehmannia glutinosa extract. The application constructs an animal model by inducing mouse kidney injury by cisplatin, and it is found that the rehmannia glutinosa extract obtained by further separating the rehmannia glutinosa water extract by using solvents such as ethyl acetate and ethanol can improve acute kidney injury caused by cisplatin, and the effect is better than that of the rehmannia glutinosa water extract.

This invention belongs to the field of biomedical technology, specifically disclosing the use of neuron-derived neurotrophic factors in the preparation of drugs for the prevention and treatment of kidney stones. Using a glyoxylate-induced mouse model of kidney calcium deposition, this invention demonstrates that neuron-derived neurotrophic factors can significantly reduce kidney calcium deposition, alleviate renal tubular structural damage, and improve renal function indicators. This achieves comprehensive intervention in the entire process of kidney stone disease, from crystal formation to tissue damage to functional abnormalities, exhibiting superior technical effects compared to single stone-dissolving or stone-expelling strategies, and possesses significant application value and clinical translational potential.

The application provides application of a TAS2R4 agonist in preparation of a drug for treating and preventing diabetic nephropathy, and comprises that a bitter taste receptor 4 subtype (TAS2R4) can be used as a drug target point for treating and preventing diabetic nephropathy, and quinine is used as a TAS2R4 agonist. Specifically, mouse diabetic nephropathy induced by a chemical reagent and mouse podocyte cell line MPC cell damage caused by chronic high glucose are taken as research objects, it is found that mouse TAS2R4 agonist quinine has a prevention and treatment effect on diabetic nephropathy, has a protection effect on podocyte loss caused by high glucose, and has an activation effect on mouse kidney TAS2R4 molecular signal, and a possible molecular mechanism is discussed from the aspects of inhibiting NLRP3 inflammasome activation and NF-kappa B signal activation path, and theoretical basis and technical support are provided for prevention and treatment of diabetic nephropathy, other kidney diseases with inactivation of TAS2R4 molecular signal and other diseases by using TAS2R4 agonists including quinine.

This invention has discovered that the pathogenesis of kidney stones is accompanied by a significant increase in the lactation modification level of histidine at position 147 of ALDOB. Furthermore, when histidine at position 147 is mutated, the lactation modification at position 147 of the mutant amino acid disappears. In vivo experiments show that this mutation can significantly inhibit the accumulation of calcium oxalate crystals in mouse kidneys, preventing the occurrence of kidney stones. Based on this, this invention provides a novel agent and pathway for the prevention and treatment of kidney stones.

COL3A1 as a marker for detecting kidney stones and its application. The application discloses a new use of COL3A1 as a specific detection marker for kidney stones, and a kit, a detection method and application for detecting kidney stones based on the expression level of COL3A1. Through cross-species transcriptome sequencing, qRT-PCR, Western blot and immunofluorescence verification of human kidney stone clinical samples and mouse kidney stone models, it is confirmed that COL3A1 is significantly up-regulated in kidney tissues of kidney stone lesions, and can be used as a molecular marker for distinguishing kidney stone patients from healthy people. The detection method provided by the application has high specificity and sensitivity, and can realize early screening, auxiliary diagnosis, disease monitoring and recurrence risk assessment of kidney stones, and provides a new molecular target and non-invasive detection scheme for clinical diagnosis of kidney stones.

The invention provides application of Qixuekang in preparation of a medicine for treating renal fibrosis. Experimental research proves that the Qixuekang administration can remarkably recover the renal function of a mouse with renal fibrosis in senescence-accompanied chronic kidney diseases, reduce the mouse kidney mesenchymal fibrosis level and the levels of fibrosis markers alpha-SMA and Col1, recover the content of reductive glutathione in the mouse, improve the activity of superoxide dismutase and improve the curative effect of the kidney fibrosis in the senescence-accompanied chronic kidney diseases. Therefore, kidney fibrosis phenotypes and fibrosis-related biochemical indexes of mice are improved. Qi-blood Kang can remarkably restore kidney mesenchymal transformation related gene and protein expression, and kidney fibrosis phenotypes in chronic kidney diseases are improved by reducing related inflammatory media; qiwankang can significantly improve mitochondrial membrane potential, increase mitochondrial neogenesis related gene expression and reduce generation of active oxygen.

The application discloses a kind of high-purity mouse kidney microvascular endothelial cell separation culture methods, belong to cell culture technical field.The separation culture method of the application includes the following steps: (1) enzymolysis digestion;(2) multi-stage filtration impurity removal;(3) differential adhesion initial purification and (4) immunomagnetic bead sorting.The application can significantly improve the purity of mouse kidney microvascular endothelial cells by using the strategy of "enzymolysis-differential adhesion-magnetic bead sorting", especially combined with the step of removing fibroblasts by differential adhesion, is the key to obtain high-quality primary cells.The purity of mouse kidney microvascular endothelial cells obtained by the separation culture method of the application can reach more than 95%, and maintains good biological activity, effectively solves the problem of serious cell contamination in the prior art.